Shedding of Ann Arbor strain live attenuated influenza vaccine virus in children 6-59 months of age

Vaccine

Volumn 29, Issue 26, 2011, Pages 4322-4327

  Mallory, Raburn M ^a   Yi, Tingting ^a   Ambrose, Christopher S ^a  

^a MEDIMMUNE   (United States)

Author keywords

Ann arbor strain; Children; Live attenuated influenza vaccine; Reactogenicity events; Shedding

Indexed keywords

INFLUENZA VACCINE;

ABDOMINAL PAIN; ARBOVIRUS; ARTICLE; CHILD; CHILL; CLINICAL ASSESSMENT; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DRUG SAFETY; EPISTAXIS; FEMALE; HEADACHE; HUMAN; INFANT; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MONITOR; MULTICENTER STUDY; NONHUMAN; OTITIS MEDIA; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RECIPIENT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHINORRHEA; RNA VIRUS INFECTION; SIDE EFFECT; SINGLE DRUG DOSE; SORE THROAT; STREPTOCOCCAL PHARYNGITIS; TOOTH ERUPTION; VIRUS CULTURE; VIRUS DETECTION; VIRUS INFECTION; VIRUS SHEDDING; VIRUS STRAIN; VIRUS TRANSMISSION; VOMITING;

ADMINISTRATION, INTRANASAL; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; TREATMENT OUTCOME; VACCINATION; VACCINES, ATTENUATED; VIRUS SHEDDING;

EID: 79957815722     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.04.022     Document Type: Article

References (17)

1. Maassab H.F. Plaque formation of influenza virus at 25 degrees C. Nature 1968, 219:645-646.
2. Maassab H., DeBorde D., Donabedian A., Smitka C. Development of cold-adapted " master" strains for type-B influenza virus vaccines. Vaccines 1985, vol. 85:327-332. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
3. Maassab H.F., Kendal A.P., Abrams G.D., Monto A.S. Evaluation of a cold-recombinant influenza virus vaccine in ferrets. J Infect Dis 1982, 146:780-790.
4. Talbot T.R., Crocker D.D., Peters J., Doersam J.K., Ikizler M.R., Sannella E., et al. Duration of virus shedding after trivalent intranasal live attenuated influenza vaccination in adults. Infect Control Hosp Epidemiol 2005, 26:494-500.
5. Murphy B.R., Coelingh K. Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines. Viral Immunol 2002, 15:295-323.
6. Block S.L., Yogev R., Hayden F.G., Ambrose C.S., Zeng W., Walker R.E. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age. Vaccine 2008, 26:4940-4946.
7. Vesikari T., Karvonen A., Korhonen T., Edelman K., Vainionpaa R., Salmi A., et al. A randomized double-blind study of the safety, transmissibility, and phenotypic and genotypic stability of cold-adapted influenza virus vaccine (LAIV, FluMist®). Pediatr Infect Dis J 2006, 25:590-595.
8. Anderson E.L., Newman F.K., Maassab H.F., Belshe R.B. Evaluation of a cold-adapted influenza B/Texas/84 reassortant virus (CRB-87) vaccine in young children. J Clin Microbiol 1992, 30:2230-2234.
9. Edwards K.M., King J.C., Steinhoff M.C., Thompson J., Clements M.L., Wright P.F., et al. Safety and immunogenicity of live attenuated cold-adapted influenza B/Ann Arbor/1/86 reassortant virus vaccine in infants and children. J Infect Dis 1991, 163:740-745.
10. Murphy B.R. Use of live attenuated cold-adapted influenza reassortant virus vaccines in infants, children, young adults, and elderly adults. Infect Dis Clin Pract 1993, 2:174-181.
11. Sears S.D., Clements M.L., Betts R.F., Maassab H.F., Murphy B.R., Snyder M.H. Comparison of live, attenuated H1N1 and H3N2 cold-adapted and avian-human influenza A reassortant viruses and inactivated virus vaccine in adults. J Infect Dis 1988, 158:1209-1219.
12. Fiore A.E., Uyeki T.M., Broder K., Finelli L., Euler G.L., Singleton J.A., et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010, 59:1-62.
13. Pearson M.L., Bridges C.B., Harper S.A. Influenza vaccination of health-care personnel: recommendations of the Healthcare Infection Control Practices Advisory Committee (HICPAC) and the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006, 55:1-16.
14. Belshe R.B., Edwards K.M., Vesikari T., Black S.V., Walker R.E., Hultquist M., et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007, 356:685-696.
15. Belshe R.B., Mendelman P.M., Treanor J., King J., Gruber W.C., Piedra P., et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med 1998, 338:1405-1412.
16. Piedra P.A., Yan L., Kotloff K., Zangwill K., Bernstein D.I., King J., et al. Safety of the trivalent, cold-adapted influenza vaccine in preschool-aged children. Pediatrics 2002, 110:662-672.
17. Zangwill K.M., Droge J., Mendelman P., Marcy S.M., Partridge S., Chiu C.Y., et al. Prospective, randomized, placebo-controlled evaluation of the safety and immunogenicity of three lots of intranasal trivalent influenza vaccine among young children. Pediatr Infect Dis J 2001, 20:740-746.